175 related articles for article (PubMed ID: 22797844)
1. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.
Mackenzie IS; Macdonald TM; Thompson A; Morant S; Wei L
BMJ; 2012 Jul; 345():e4447. PubMed ID: 22797844
[TBL] [Abstract][Full Text] [Related]
2. [Increased breast cancer risk caused by spironolactone?].
Fanta S
Dtsch Med Wochenschr; 2012 Sep; 137(38):1840. PubMed ID: 23133848
[No Abstract] [Full Text] [Related]
3. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.
Mackenzie IS; Morant SV; Wei L; Thompson AM; MacDonald TM
Br J Clin Pharmacol; 2017 Mar; 83(3):653-663. PubMed ID: 27735065
[TBL] [Abstract][Full Text] [Related]
4. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?
Korol S; White M; O'Meara E; Rouleau JL; White-Guay B; Dorais M; Ahmed A; de Denus S; Perreault S
Eur J Clin Pharmacol; 2019 Jun; 75(6):837-847. PubMed ID: 30758517
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.
Bhaskaran K; Douglas I; Evans S; van Staa T; Smeeth L
BMJ; 2012 Apr; 344():e2697. PubMed ID: 22531797
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone and gastrointestinal bleeding: a population based study.
Russo A; Autelitano M; Bisanti L
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):495-500. PubMed ID: 18327868
[TBL] [Abstract][Full Text] [Related]
7. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis.
Wei C; Bovonratwet P; Gu A; Moawad G; Silverberg JI; Friedman AJ
J Am Acad Dermatol; 2020 Oct; 83(4):1021-1027. PubMed ID: 32446820
[TBL] [Abstract][Full Text] [Related]
8. Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
Tseng WC; Liu JS; Hung SC; Kuo KL; Chen YH; Tarng DC; Hsu CC
Int J Cardiol; 2017 Jul; 238():72-78. PubMed ID: 28363684
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone use and the risk of breast and gynecologic cancers.
Biggar RJ; Andersen EW; Wohlfahrt J; Melbye M
Cancer Epidemiol; 2013 Dec; 37(6):870-5. PubMed ID: 24189467
[TBL] [Abstract][Full Text] [Related]
10. Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
Chen LC; Yang HJ; Yu BH; Lee MS; Lin HY; Chiou WY; Liu DW; Hsu FC; Chew CH; Hung SK
PLoS One; 2024; 19(3):e0300391. PubMed ID: 38536840
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
Secora AM; Shin JI; Qiao Y; Alexander GC; Chang AR; Inker LA; Coresh J; Grams ME
Mayo Clin Proc; 2020 Nov; 95(11):2408-2419. PubMed ID: 33153631
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy.
Chung YW; Yang YH; Wu CK; Yu CC; Juang JM; Wang YC; Tsai CT; Lin LY; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL
Int J Cardiol; 2016 Jan; 202():962-6. PubMed ID: 26323866
[TBL] [Abstract][Full Text] [Related]
14. Incident malignancies among older long-term breast cancer survivors and an age-matched and site-matched nonbreast cancer comparison group over 10 years of follow-up.
Clough-Gorr KM; Thwin SS; Bosco JL; Silliman RA; Buist DS; Pawloski PA; Quinn VP; Prout MN
Cancer; 2013 Apr; 119(8):1478-85. PubMed ID: 23280284
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of spironolactone in a specialized heart failure clinic.
Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients.
Conrad N; Judge A; Canoy D; Tran J; O'Donnell J; Nazarzadeh M; Salimi-Khorshidi G; Hobbs FDR; Cleland JG; McMurray JJV; Rahimi K
PLoS Med; 2019 May; 16(5):e1002805. PubMed ID: 31112552
[TBL] [Abstract][Full Text] [Related]
17. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
Cavallari LH; Groo VL; Viana MA; Dai Y; Patel SR; Stamos TD
Pharmacotherapy; 2010 Jan; 30(1):1-9. PubMed ID: 20030467
[TBL] [Abstract][Full Text] [Related]
18. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
Shah KB; Rao K; Sawyer R; Gottlieb SS
J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
[TBL] [Abstract][Full Text] [Related]
19. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
20. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
